Novartis AG's Kymriah (tisagenlecleucel) is on track for a regulatory filing in an expanded indication – relapsed/refractory follicular lymphoma – that would give the CD19-targeting CAR-T therapy a similar indication to one already granted to Gilead Sciences, Inc.'s rival product, Yescarta (axicabtagene ciloleucel).
Novartis announced positive data from the pivotal Phase II ELARA trial in relapsed/refractory (r/r) follicular lymphoma on 2 June and...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

